NCT05124743 — Alaunos Therapeutics neoantigen vaccine trial
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Registry record
| Registry ID | NCT05124743 ↗ |
|---|---|
| Lead sponsor | Alaunos Therapeutics |
| Collaborators | M.D. Anderson Cancer Center |
| Phase | — |
| Status | Terminated |
| Indication | Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma, Non-small Cell Lung Cancer, Pancreas Cancer |
| Enrollment | 19 participants (target) |
| Start date | 2021-10-07 |
| Primary completion | 2023-03-23 |
| Last registry update | 15 Oct 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05124743), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT05124743?
NCT05124743 (HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors) is registered on ClinicalTrials.gov as having no assigned phase, sponsored by Alaunos Therapeutics.
Is NCT05124743 recruiting?
As of the 2026-10-15 registry update, NCT05124743 is listed as "Terminated". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05124743?
The lead sponsor is Alaunos Therapeutics. Collaborators: M.D. Anderson Cancer Center.
What condition does NCT05124743 study?
The registered conditions are Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma, Non-small Cell Lung Cancer, Pancreas Cancer. Primary completion is listed as 2023-03-23.
Are results available for NCT05124743?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05124743.
Back to the full neoantigen vaccine trial tracker — 106 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.